Haematologica

Article	Citations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	151
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	114
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	107
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	105
The first human acute myeloid leukemia genome ever fully sequenced	96
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	66
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	65
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	64
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	61
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	60
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	59
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	58
Acute myeloid leukemia at first relapse: approaching the precipice	56
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	51
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	50
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	50
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	50
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	48
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R	48
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide	47
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience	45
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	44
Asparaginase-associated hyperammonemia	43
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma	42
<i>Erratum</i> to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice”	41

Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	41
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	41
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	40
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	39
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	39
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	38
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	38
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	38
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	37
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	36
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review	36
Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis	36
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials	35
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	35
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	35
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	35
Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma	35
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	34
CD47 expression in acute myeloid leukemia varies according to genotype	33
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	33
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	32
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	32
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	32
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism	31
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry	30
First-line MAPK inhibition in pediatric histiocytosis: are we ready?	30
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study	30
Running chromosome analysis in leukemia or not, upfront or later?	30
Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine	30
Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor	30
New bullets in the fight against cancer	29
MAPK-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis	29
Extracranial internal carotid artery and cerebral infarction in paediatric sickle cell patients	27
Chronic lymphocytic leukemia and associated chronic lung diseases	27
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia	27
Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of <i>PCM1::JAK2</i> with erythroblastic sarcoma: a case report and literature review	27
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program	26
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia	26
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma	26
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments	26
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report	26
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy	26
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)	25
COVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation	25
Safe platelet count for lumbar puncture: are we being overcautious?	25
Mutations in the <i>RACGAP1</i> gene cause autosomal recessive congenital dyserythropoietic anemia type III	24
Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’	24
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KM	24
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	24
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia	24

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase	23
TNF-α signaling drives myeloid skewing and clonal expansion of stem and progenitors in <i>RUNX1</i>-familial platelet disorder	23
Treatment of lower-risk myelodysplastic syndromes	23
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia	23
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation	23
The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease	23
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study	23
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen	23
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	23
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients	23
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial	22
How we changed our approach to venous thromboembolism	22
Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience	22
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis	22
Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes	22
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia	22
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients	22
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	22
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on vire	22
IgM monoclonal gammopathies of clinical significance: diagnosis and management	22
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice	21
Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma	21
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden	21
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia	21
Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP	21
Getting (T cells) ENGaged	21
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	21
Aspirin is a life-saving drug for patients with acute myocardial infarction	21
COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism	21
Teclistamab therapy for refractory type 1 cryoglobulinemia Teclistamab in type 1 cryoglobulinemia	20
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria	20
HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma	20
A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis	20
“Bridegroom of blood”- A biblical reference to hemophilia?	20
Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell	20
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums	20
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma	19
von Hippel- Lindau syndrome-related congenital polycythemia and response to belzutifan	19
<i>Ex vivo</i> correction of severe coagulation Factor VII deficiency in patient-derived 3D liver organoids	19
The French-American-British classification system for acute myeloid leukemia	19
Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria	19
Duality of Nrf2 in iron-overload cardiomyopathy	18
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome	18
Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A</i>-rearranged acute myeloid leukemia	18
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma	18
An investigation of germline variants of <i>HAVCR2</i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population	18
Reply to the Comment on: “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”	18
Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness	18
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma	18
The International Prognostic Index: still relevant 30 years later	18
STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of <i>BCL2</i> and <i>BCLXL</i> following glucocorticoid treatment	18
Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia	17
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation	17
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	17
Type I interferons: leukemia's old foe in the limelight again	17
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries	17
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma	17
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials	17
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemia	17
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes	17
Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era	17
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?	17
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Work	17
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	17
Entities <i>versus</i> diseases: Myers <i>et al</i>. propose distinct aspects of adult T-cell lymphoma / leukemia.	16
More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune	16
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and <i>SF3B1</i> mutations	16
Home time among older adults with acute myeloid leukemia by therapy intensity	16
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria	16
Introduction. Immunotherapy for childhood malignancies: the future is now	16
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding	16
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-ce	16
Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation	16
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.	16
Leon's helmet	16
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T	16
Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade	16
Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect	16
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors	15
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome	15

An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir	15
Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD-19-directed immunotherapy	15
Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis	15
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings	15
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow	15
A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment	15
Association of <i>NUDT15</i> gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review an	15
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes	15
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma	15
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?	15
CCRL2 and who? An important driver in <i>TP53-</i>mutant myeloid leukemias	15
<i>Erratum</i> to: Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study	15
Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States	15
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options	15
The effects of cardio-selective β blockade on diastolic dysfunction in children with sickle cell disease	15
The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia	14
Sex differences in progression of kidney disease in sickle cell disease	14
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortali	14
Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration	14
Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma	14
Delving the depths of measurable residual disease negativity in acute myeloid leukemia	14
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study	14
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy	14
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States	14
Somatic genetic alterations predict hematological progression in GATA2 deficiency	14
Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.	14
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma	14
Amyloidogenic light chains impair plasma cell survival	14
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis	14
Response to the Comment: “Advocating prudent D-dimer testing: constructive perspectives and comments on “How we manage a high D-dimer”	14
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children	14
Acute leukemia of ambiguous lineage: the known and the uncertain	14
Lipid dysregulation after hematopoietic stem cell transplant	14
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia	14
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly related	13
Evaluation of the <i>ATM</i> L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms	13
The landmark contribution by Erik von Willebrand	13
RNA helicase DHX15 exemplifies a unique dependency in acute leukemia	13
Immunosuppression with post-transplant cyclophosphamide for allogeneic hematopoietic cell transplantation	13
Do it once, but do it right	13
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemia	13
The double-edged sword of adenosine	13
Ethnicity in systemic AL amyloidosis may impact risk stratification	13
Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment	13
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse	13
Treatment-related mutagenic processes in acute lymphoblastic leukemia	13
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application	13
Artificial intelligence-based Myelodysplastic Syndromes Score, 2022 classifications, and the Molecular International Prognostic Scoring System: a perfect match	13
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, <i>TP53</i> alterations and poor prognosis	13
Arkadia: a new player in hematopoietic stem and progenitor cell development	13
<i>ASXL1</i> mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms	13
Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab	13
MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia	12
Clinical and molecular features of <i>CBL</i>-mutated juvenile myelomonocytic leukemia	12
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis	12
Treatment of drug-induced immune thrombocytopenias	12
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual di	12
Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial	12
Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective coho	12
Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis	12
Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia	12
Sorting nexin 24 is required for α-granule biogenesis and cargo delivery in megakaryocytes	12
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A	12
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes	12
The immunophenotypic and genetic characterization of pediatric T -L ymphoblastic leukemia with a mature immunophenotype	12
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial	12
B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/βresponse in bone marrow-derived mesenchymal stroma	12
Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with cli	12
Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study	12
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopo	12
Hematopoietic cell transplants for acute leukemias	12
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical <i>STIL</i>::<i>TAL1</i> fusion events	12
Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis	12
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia	12
Do older patients truly benefit from advances in myeloma care?	11
Evolution in treatment of acute promyelocytic leukemia: a major victory	11
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting	11
A case series of patients with β-thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies	11
Anatomy of a crime: how IL7R and NRAS join forces to drive T-cell acute lymphoblastic leukemia	11
Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia	11
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis	11
Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring <i>ELANE</i> mutations	11
Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers	11
Beyond adenosine triphosphate: unveiling the pleiotropic effects of pyruvate kinase activation in sickle cell anemia	11
Nandrolone decanoate: new therapeutic option for telomeropathies?	11
Expanding the bacterial origins of nodular lymphocyte-predominant Hodgkin lymphoma	11
Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance	11
Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation	11
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant	11
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma	11
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials	11
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors	11
One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy	11
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm	11
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	11